[Effect of 0.1% diclofenac ophthalmic solution on inflammatory response and macular thickness following phacoemulsification cataract surgery]

Klin Oczna. 2016;118(4):270-7.
[Article in Polish]

Abstract

Purpose: To evaluate 0.1% diclofenac sodium as an adjunctive therapy with loteprednol etabonate on postoperative inflammation in the anterior chamber and on foveal and parafoveal retinal thickness.

Material and methods: Eighty eyes eligible for phacoemulsification were enrolled in a randomized clinical trial. Patients in group I (N = 40) received anti-inflammatory treatment consisting of 0.1% diclofenac with 0.5% loteprednol; group II (N = 40) patients received 0.5% loteprednol alone. Best corrected visual acuity and intraocular pressure were measured, and laser flarephotometry was done. Foveal and parafoveal thickness were assessed by optical coherence tomography. Results: Median flare values decreased more rapidly in group I at 7 and 14 days (7.9 and 7.4 ph/ms, respectively) than in group II (13.7 and 11.8 ph/ms, respectively; p < 0.0001). Group II had significantly increased parafoveal thickness at 14 and 42 days (median 285.59 μm, p = 0.001 and 288.38 μm, p < 0.001, respectively). Parafoveal thickness differed significantly between groups at 14 and 42 days (p = 0.0085, p = 0.0004, respectively).

Conclusions: Eyes treated with both diclofenac sodium and loteprednol etabonate showed less inflammatory response and were less likely to develop foveal and parafoveal thickening than those treated with steroid only.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Aged
  • Aged, 80 and over
  • Anterior Chamber / drug effects
  • Anterior Chamber / pathology*
  • Diclofenac / therapeutic use*
  • Drug Therapy, Combination
  • Female
  • Humans
  • Inflammation / diagnostic imaging
  • Inflammation / drug therapy*
  • Inflammation / etiology
  • Intraocular Pressure
  • Loteprednol Etabonate / therapeutic use*
  • Macula Lutea / diagnostic imaging
  • Macula Lutea / drug effects
  • Macula Lutea / pathology*
  • Male
  • Middle Aged
  • Phacoemulsification / adverse effects*
  • Postoperative Complications / diagnostic imaging
  • Postoperative Complications / drug therapy
  • Postoperative Complications / etiology
  • Prospective Studies
  • Protective Agents / therapeutic use
  • Tomography, Optical Coherence
  • Treatment Outcome
  • Visual Acuity

Substances

  • Protective Agents
  • Diclofenac
  • Loteprednol Etabonate